Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 8 recruiting now early-phase tilt small index

Fanconi Anemia: early-phase trial registry

8 of 16 indexed Fanconi Anemia trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,060 of 28,707 conditions by registered trial count.

16 US clinical trials · 8 currently recruiting · #1,060 of 28,707 conditions by registered trial count

Fanconi Anemia: 16 US clinical trials tracked, 8 recruiting.

Fanconi Anemia is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 8 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Masonic Cancer Center, University of Minnesota, running 3 of these trials.

Enrollment posture brief

Registry condition fanconi-anemia

OPEN 8 | RECR 50% | LATE 0 | EARLY 9 | RANK #1060 | SPON 3

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Adolescent62.5%Alcohol Intoxication56.3%Fanconi Anemia (this)50%AL Amyloidosis43.8%Allergy18.8%
Open-enrollment share among volume-matched conditions near Fanconi Anemia

Fanconi Anemia lists 8 open slots (50% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Fanconi Anemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Fanconi Anemia is recruiting above its size-band peers.

    8 of 16 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Fanconi Anemia research.

    Masonic Cancer Center, University of Minnesota accounts for 3 of 16 trials (18.8%). 10 distinct sponsors appear on at least one study for this condition label.

  3. Most Fanconi Anemia trials plan to enrol fewer than 100 people.

    Median target enrolment is 40 among the 16 trials that report a genuine target (sentinel values excluded). 12 of those (75%) plan for fewer than 100 participants.

  4. Fanconi Anemia research is mostly interventional.

    13 interventional and 3 observational studies make up this index (81.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 27

Open and recent trials

16 total, page 1 of 1

RECRUITING 4,000 participants

Cancer in Inherited Bone Marrow Failure Syndromes

National Cancer Institute (NCI)

NCT00027274

RECRUITING 200 participants

Defining the Natural History of Squamous Cell Carcinoma in Fanconi Anemia

National Cancer Institute (NCI)

NCT05687149

RECRUITING NA 170 participants

Role of Acetaldehyde in the Development of Oral Cancer

Masonic Cancer Center, University of Minnesota

NCT05973656

RECRUITING Phase 2 70 participants

HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy

Children's Hospital Medical Center, Cincinnati

NCT02143830

RECRUITING Phase 2 48 participants

Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders

Masonic Cancer Center, University of Minnesota

NCT03579875

RECRUITING Phase 2 27 participants

Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04232085

RECRUITING 20 participants

Experience and Management of Cancer Screening-Related Anxiety in Fanconi Anemia

National Cancer Institute (NCI)

NCT06744283

RECRUITING Phase 1 18 participants

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

Porteus, Matthew, MD

NCT04784052

ACTIVE NOT RECRUITING NA 338 participants

Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer

M.D. Anderson Cancer Center

NCT00542373

ACTIVE NOT RECRUITING Phase 2 48 participants

Quercetin Chemoprevention for Squamous Cell Carcinoma in Patients With Fanconi Anemia

Children's Hospital Medical Center, Cincinnati

NCT03476330

ACTIVE NOT RECRUITING Phase 2 25 participants

Eltrombopag for People With Fanconi Anemia

National Heart, Lung, and Blood Institute (NHLBI)

NCT03206086

COMPLETED Phase 1 40 participants

Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

University of California, San Francisco

NCT00305708

COMPLETED NA 21 participants

Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine

Memorial Sloan Kettering Cancer Center

NCT00595127

COMPLETED Phase 2 14 participants

Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

Masonic Cancer Center, University of Minnesota

NCT00258427

COMPLETED NA 3 participants

Time-restricted Feeding to Reduce Inflammation in Fanconi Anemia

Children's Hospital Medical Center, Cincinnati

NCT05598515

COMPLETED Phase 2 1 participants

Hematopoietic Stem Cell Transplant for Fanconi Anemia

Medical College of Wisconsin

NCT01071239

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 7

Named interventions

Most-linked intervention names on Fanconi Anemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cyclophosphamide Drug
5 trials
Fludarabine Drug
4 trials
anti-thymocyte globulin Biological
2 trials
busulfan Drug
2 trials
fludarabine phosphate Drug
2 trials
Busulfan Drug
2 trials
CliniMACs device Device
1 trials
Total body irradiation (TBI) Radiation
1 trials

US sites by state

Facility locations filed on Fanconi Anemia trials. A trial with sites in several states counts in each.

Maryland 5 trials
Ohio 3 trials
Minnesota 3 trials
New York 2 trials
California 2 trials
Wisconsin 1 trials
Washington 1 trials
Texas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Fanconi Anemia page

16 registered trials, 8 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Fanconi Anemia condition card totals 16 registered trials; most-linked intervention Cyclophosphamide; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.